Moderna Stock Pops on Surprise Earnings Beat
An unexpected profit and promising news on a deal with the EU boosted Moderna stock.

Shares in Moderna (MRNA) rose smartly Thursday after the COVID-19 vaccine maker reported better-than-expected earnings and said it was in "active supply discussions" with the European Union.
Explosive demand for the biotechnology firm's coronavirus vaccine allowed MRNA stock to generate outstanding returns during the first year-and-a-half of the pandemic. Shares peaked almost two years ago, however, as global vaccination rates rose and new COVID-19 cases tapered off. As a result, Moderna stock has lost about a quarter of its value in 2023 alone.
The company's coronavirus vaccine is its only marketable product. As such, Moderna is racing to develop and bring new drugs to market in order to find growth in the post-pandemic era.

Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
For the first quarter ended March 31, Moderna reported net income of $79 million, or 19 cents per share. Although that represented a 98% decrease from net income of $3.7 billion, or $8.58 per share, recorded in last year's Q1, the results easily topped Wall Street estimates. Indeed, analysts surveyed by S&P Global Market Intelligence forecast Moderna to post a net loss of $1.75 a share.
Total revenue fell 69% to $1.9 billion from $6.1 billion in last year's first quarter. Analysts were looking for Moderna to report revenue of $1.2 billion. The company beat the Street's top-line forecast thanks to revenue deferred from 2022.
Moderna vaccine launches on tap
Moderna has next generation COVID-19 vaccines under development, as well as vaccinations for influenza and respiratory syncytial virus (RSV). Other areas of research include immuno-oncology, rare diseases, autoimmune diseases and cardiovascular diseases.
"Importantly, Moderna is preparing for six major vaccine launches from its respiratory franchise, with expected annual sales of $8 billion to $15 billion by 2027," notes Lee Brown, global sector lead for healthcare at research firm Third Bridge. "The company also plans to begin a Phase 3 trial of mRNA-4157, an individualized neoantigen therapy (INT) in combination with Keytruda for melanoma. mRNA-4157 has the potential to profoundly change the treatment of melanoma."
For now, however, Moderna remains a one-trick COVID-19 vaccine pony. Helpfully, it gave investors a shot of good news on that front following its earnings report.
Moderna CEO Stéphane Bancel said the company is in discussions with the European Union to supply Europe with vaccines for the fall of 2023 – a time when new coronavirus cases are expected to pick up. MRNA shareholders were deeply concerned by media reports surfacing early this week that Moderna could be shut out of the European COVID-19 vaccine market.
MRNA stock added more than 6% at one point in early intraday trading, but it still has a long way to go to reclaim anything like its all-time highs. Shares have lost almost three-quarters of their value since setting a record close in August 2021.
Although the selloff has made the valuation more attractive, Wall Street remains somewhat split on whether MRNA stock offers a good entry point. Of the 21 analysts covering the stock surveyed by S&P Global Market Intelligence, six call it a Strong Buy, five say Buy, nine have it at Hold and one says Sell. That works out to a consensus recommendation of Buy, with mixed conviction.
Analysts' price targets also reflect widely different outcomes. Although the Street's average price target of $218.88 gives MRNA stock implied upside of 60% in the next year or so, those targets range from a high of $430 a share to a low of $93. Should the Street's most bearish forecast come to pass, MRNA would fall roughly 30% from current levels.
Dan Burrows is Kiplinger's senior investing writer, having joined the august publication full time in 2016.
A long-time financial journalist, Dan is a veteran of SmartMoney, MarketWatch, CBS MoneyWatch, InvestorPlace and DailyFinance. He has written for The Wall Street Journal, Bloomberg, Consumer Reports, Senior Executive and Boston magazine, and his stories have appeared in the New York Daily News, the San Jose Mercury News and Investor's Business Daily, among other publications. As a senior writer at AOL's DailyFinance, Dan reported market news from the floor of the New York Stock Exchange and hosted a weekly video segment on equities.
In his current role at Kiplinger, Dan writes about equities, fixed income, currencies, commodities, funds, macroeconomics, demographics, real estate, cost of living indexes and more.
-
-
The NBA Finals and the Jock Tax
State Taxes The 'jock tax' impacts pro athletes and other people who travel for business with sports teams and earn income in different states.
By Kelley R. Taylor • Published
-
Where Inflation is Rising the Most
These are the top 10 metro areas where inflation is increasing the most.
By Erin Bendig • Published
-
Stock Market Today: Stocks Slide as Regional Bank Rout Worsens
The major market indexes closed lower Thursday as chaos in the banking industry continued.
By Karee Venema • Published
-
The 9 Best Healthcare Stocks to Buy
The best healthcare stocks offer investors a defensive hedge in an uncertain market.
By Deborah Yao • Published
-
Stock Market Today: Stocks Score a Hard-Fought Win to Start the Week
Stock Market Today Price action will likely stay choppy ahead of Wednesday's Fed decision.
By Karee Venema • Published
-
The 21 Top S&P 500 Stocks Since the Bear-Market Bottom
stocks Growth stocks have been some of the best performers since the June low.
By Dan Burrows • Published
-
Stock Market Today: Stocks Resume Rally on Strong Earnings, Economic Data
Stock Market Today The ISM services index and the latest reading on factory orders both came in higher than expected.
By Karee Venema • Published
-
25 Best S&P 500 Stocks of the Pandemic Bull Market
stocks Work-from-home stocks and home-improvement retailers might have been the stars of the COVID bull's first half, but they didn't finish on top.
By Dan Burrows • Published
-
5 Stock Picks With Bulletproof Profit Margins
stocks to buy Companies that can squeeze a lot of blood from the revenue stone can flourish, even in tough times.
By Nellie S. Huang • Published
-
Stock Market Today: Russian Invasion Sparks Roller-Coaster Day for Stocks
Stock Market Today Stocks initially opened deep in the red on news of Russia's full-scale attack on Ukraine.
By Karee Venema • Published